UBS provides market analysis on the GLP-1 sector, backing Eli Lilly and tracking Novo Nordisk as a major competitor.
3 reports, 2 independent
Updated Sep 3
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS provides market analysis on the GLP-1 sector, backing Eli Lilly and tracking Novo Nordisk as a major competitor.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Weekly tracker published detailing Novo Nordisk's GLP-1 asset performance.1 source
UBS is bullish on Eli Lilly's leadership in the GLP-1 market against Novo Nordisk.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
UBS
Swiss multinational investment bank and financial services company
Related events
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.